Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FACIOX UV
- Development stage
- Unknown
- Lead developer
- JACKS
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
FACIOX UV is a topical sunscreen product developed and marketed by Jaks Pharma. It is formulated as a gel designed for dermatological skin care, providing broad-spectrum protection against ultraviolet (UV) radiation. The product typically contains a combination of chemical UV filters and physical blockers, such as octyl methoxycinnamate, avobenzone, oxybenzone, and zinc oxide, which work together to absorb, reflect, and scatter UVA and UVB rays. This mechanism helps prevent sunburn, premature skin aging (photoaging), and reduces the long-term risk of UV-induced skin damage. It is commercially available and approved for use as a protective skin care agent.
- Brand names
- FACIOX UV
Beyond the preview
Go deeper on FACIOX UV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FACIOX UV.